Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021 - December 2023)

Introduction Breast cancer is the most frequently diagnosed cancer worldwide. With around 70% of breast cancers expressing the estrogen receptor (ER), molecules capable of antagonizing and degrading ER (SERDs) or covalently binding to and antagonizing ER (SERCAs) are at the forefront of efforts to bring better treatments to patients.